Guselkumab

BNF:

Skin

Status:

Red

Decision Date:

July 2018

Comments

RED: NICE TA521: for the treatment of moderate-to-severe plaque psoriasis in adults.

RED: NICE TA815 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (Decision date - September 2022)

CCG's are the responsible commissioners.

 

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again